$60,000 of BRIDGEBIO PHARMA lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals."
You can find more data on corporate lobbying on Quiver Quantitative.
BBIO Congressional Stock Trading
Members of Congress have traded $BBIO stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 09/22, 08/08 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
BBIO Insider Trading Activity
BBIO insiders have traded $BBIO stock on the open market 93 times in the past 6 months. Of those trades, 0 have been purchases and 93 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:
- NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 67 sales selling 562,323 shares for an estimated $34,400,034.
- FRANK MCCORMICK has made 0 purchases and 7 sales selling 274,000 shares for an estimated $17,246,736.
- CHARLES J HOMCY has made 0 purchases and 3 sales selling 300,000 shares for an estimated $13,912,442.
- ANDREW LO has made 0 purchases and 4 sales selling 95,599 shares for an estimated $6,319,662.
- THOMAS TRIMARCHI (President and CFO) has made 0 purchases and 5 sales selling 76,524 shares for an estimated $4,087,207.
- RONALD J DANIELS sold 61,031 shares for an estimated $3,888,999
- HANNAH VALANTINE sold 25,484 shares for an estimated $1,683,727
- ANDREA ELLIS sold 17,167 shares for an estimated $841,183
- RANDAL W. SCOTT has made 0 purchases and 2 sales selling 10,000 shares for an estimated $666,465.
- MARICEL APULI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 3,000 shares for an estimated $193,960.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BBIO Hedge Fund Activity
We have seen 218 institutional investors add shares of BBIO stock to their portfolio, and 172 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VIKING GLOBAL INVESTORS LP removed 2,577,526 shares (-13.9%) from their portfolio in Q3 2025, for an estimated $133,876,700
- CAPITAL RESEARCH GLOBAL INVESTORS removed 2,055,172 shares (-51.5%) from their portfolio in Q3 2025, for an estimated $106,745,633
- WOODLINE PARTNERS LP removed 1,506,482 shares (-88.4%) from their portfolio in Q3 2025, for an estimated $78,246,675
- HOOD RIVER CAPITAL MANAGEMENT LLC added 1,243,545 shares (+inf%) to their portfolio in Q3 2025, for an estimated $64,589,727
- INVESCO LTD. added 1,127,592 shares (+40.3%) to their portfolio in Q3 2025, for an estimated $58,567,128
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,051,679 shares (+inf%) to their portfolio in Q3 2025, for an estimated $54,624,207
- ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC added 987,273 shares (+14211.5%) to their portfolio in Q4 2025, for an estimated $75,516,511
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BBIO Analyst Ratings
Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 01/08/2026
- Morgan Stanley issued a "Overweight" rating on 01/06/2026
- JP Morgan issued a "Overweight" rating on 11/07/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/03/2025
- Goldman Sachs issued a "Buy" rating on 10/31/2025
- Raymond James issued a "Outperform" rating on 10/30/2025
- TD Cowen issued a "Buy" rating on 10/30/2025
To track analyst ratings and price targets for BBIO, check out Quiver Quantitative's $BBIO forecast page.
BBIO Price Targets
Multiple analysts have issued price targets for $BBIO recently. We have seen 15 analysts offer price targets for $BBIO in the last 6 months, with a median target of $86.0.
Here are some recent targets:
- Danielle Brill from Truist Securities set a target price of $86.0 on 01/08/2026
- Sean Laaman from Morgan Stanley set a target price of $96.0 on 01/06/2026
- Mani Foroohar from Leerink Partners set a target price of $86.0 on 12/15/2025
- William Pickering from Bernstein set a target price of $94.0 on 12/11/2025
- Derek Archila from Wells Fargo set a target price of $84.0 on 11/11/2025
- Anupam Rama from JP Morgan set a target price of $77.0 on 11/07/2025
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $90.0 on 11/03/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
